|Title:||Novel controlled release dosage form of valproic acid|
|Abstract:||The invention relates to controlled release pharmaceutical compositions. These contain as active ingredient valproic acid, a salt of valproic acid, an ester of valproic acid, Valpromide, or any other pharmaceutically acceptable derivative of valproic acid which upon administration to humans provides a serum level of valproic acid, in combination with an additive which is selected from physiologically acceptable polymeric substances and from native proteins. The active ingredient is usually in the range of from 10 to 80 weight percent. The novel pharmaceutical compositions are prepared by applying a high pressure to a mixture of the ingredients. They result in a prolonged serum level of the active ingredient.|
|Inventor(s):||Friedman; Michael (Jerusalem, IL), Bialer; Meir (Jerusalem, IL), Rubinstein; Avraham (Jerusalem, IL), Dufrovsky; Upd (Tel-Aviv, IL)|
Patent Claim Types:|
see list of patent claims
|Compound; Dosage form; Process;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Israel||74468||Feb 28, 1985|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0442012||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.